Epilepsy priorities in Europe: A report of the ILAE-IBE Epilepsy Advocacy Europe Task Force. by Baulac, M. et al.
Epilepsy priorities in Europe: A report of the ILAE-IBE
Epilepsy Advocacy Europe Task Force
*Michel Baulac, †Hanneke de Boer, ‡Christian Elger, §MikeGlynn, ¶#Reetta K€alvi€ainen,
**Ann Little, ††JanetMifsud, ‡‡Emilio Perucca, §§Asla Pitk€anen, and ¶¶Philippe Ryvlin
Epilepsia, 56(11):1687–1695, 2015
doi: 10.1111/epi.13201
Summary: The European Forum on Epilepsy Research (ERF2013), which took place in
Dublin, Ireland, on May 26–29, 2013, was designed to appraise epilepsy research priori-
ties in Europe through consultation with clinical and basic scientists as well as repre-
sentatives of lay organizations and health care providers. The ultimate goal was to
provide a platform to improve the lives of persons with epilepsy by influencing the
political agenda of the EU. The Forum highlighted the epidemiologic, medical, and
social importance of epilepsy in Europe, and addressed three separate but closely
related concepts. First, possibilities were explored as to how the stigma and social bur-
den associated with epilepsy could be reduced through targeted initiatives at EU
national and regional levels. Second, ways to ensure optimal standards of care
throughout Europe were specifically discussed. Finally, a need for further funding in
epilepsy research within the European Horizon 2020 funding programmewas commu-
nicated to politicians and policymakers participating to the forum. Research topics dis-
cussed specifically included (1) epilepsy in the developing brain; (2) novel targets for
innovative diagnostics and treatment of epilepsy; (3) what is required for prevention
and cure of epilepsy; and (4) epilepsy and comorbidities, with a special focus on aging
and mental health. This report provides a summary of recommendations that
emerged at ERF2013 about how to (1) strengthen epilepsy research, (2) reduce the
treatment gap, and (3) reduce the burden and stigma associated with epilepsy.
Half of the 6 million European citizens with epilepsy feel stigmatized and experience
social exclusion, stressing the need for funding trans-European awareness campaigns
and monitoring their impact on stigma, in line with the global commitment of the
EuropeanCommission andwith the recommendationsmade in the 2011WrittenDec-
laration on Epilepsy. Epilepsy care has high rates ofmisdiagnosis and considerable vari-
ability in organization and quality across European countries, translating into huge
societal cost (0.2% GDP) and stressing the need for cost-effective programs of harmo-
nization and optimization of epilepsy care throughout Europe. There is currently no
cure or prevention for epilepsy, and 30% of affected persons are not controlled by cur-
rent treatments, stressing the need for pursuing research efforts in the field within
Horizon 2020. Priorities should include (1) development of innovative biomarkers and
therapeutic targets and strategies, from gene and cell-based therapies to technologi-
cally advanced surgical treatment; (2) addressing issues raised by pediatric and aging
populations, as well as by specific etiologies and comorbidities such as traumatic brain
injury (TBI) and cognitive dysfunction, toward more personalized medicine and pre-
vention; and (3) translational studies and clinical trials built upon well-established
European consortia.
KEY WORDS: Advocacy, Biomarkers, Cure, Epileptogenesis, Epilepsy, European
Commission, Horizon 2020, Research, Treatment.
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Key Points
• The European Forum on Epilepsy Research took place
in May 2013 to appraise epilepsy research priorities in
Europe through consultation of all stakeholders
• Priorities should include development of innovative
biomarkers, therapeutic targets, and strategies, along
with translational studies and clinical trials
• Specific research programs should focus on pediatric
and aging populations, as well as on comorbidities,
toward more personalized medicine and prevention
• The forum also explored how the stigma and social
burden associated with epilepsy could be reduced
through targeted initiatives at EU national and regio-
nal levels
• The forum called for EU-funded cost-effective pro-
grams of harmonization and optimization of epilepsy
care throughout Europe
The European Forum on Epilepsy Research (ERF2013)
was an initiative of Epilepsy Advocacy Europe (EAE), a
collaborative joint Task Force of the International League
Against Epilepsy (ILAE) and the International Bureau for
Epilepsy (IBE). The Forum was co-funded by the Euro-
pean Commission’s 7th Framework Programme and
hosted in conjunction with the Irish Presidency of the
Council of the EU during the European Month of the
Brain, providing an opportunity to move forward the
agenda outlined in the Written Declaration on Epilepsy
approved by the European Parliament in 2011.1 According
to this declaration, 6 million European citizens have epi-
lepsy, many of whom also have difficulties at school, high
levels of unemployment, stigma, and prejudice (see
Table 1).1 This declaration calls on the European commis-
sion and council to encourage research and innovation in
the areas of prevention, early diagnosis and treatment of
epilepsy, and in that of health impact assessments, take
initiatives to encourage Member States to ensure equal
quality of life for people with epilepsy, and calls on the
Member States to introduce appropriate legislation to pro-
tect the rights of all people with epilepsy. To address
these issues, EAE selected six main topics to be covered
during the forum: (1) Epilepsy in the Developing Brain,
(2) New Targets for Innovative Diagnosis and Treatments,
(3) What Is Required for Prevention and Cure, (4) Epi-
lepsy and Comorbidities—Linked to Healthy Aging and
Mental Health, (5) Standards of Care, and (6) Stigma.
These six topics included 27 lectures for which content
and speakers were selected by the EAE and 12 appointed
chairs based on experts’ position, without using a specific
methodology or systematic review process. A total of 270
participants from 57 countries, including each of the 27
EU Member States, were present at the Forum. The list of
speakers and government’s representatives is provided in
Data S1. This report summarizes the views expressed by
these participants during the forum, and does not consti-
tute a formal consensus statement.
Stigma and the Burden of
Epilepsy
Social exclusion and stigma largely contribute to the glo-
bal burden of epilepsy. Stigma, which is largely caused by
the lack of public awareness of the nature of the disease, is
the greatest problem faced by many people with epilepsy.9
Children with epilepsy may be banned from school, adults
may be barred from marriage, and employment is often
denied, even when seizures do not render the work unsuit-
able or unsafe.3 In a study involving >6,000 adults from 10
European countries, more than half felt stigmatized, and
18% felt highly stigmatized because of their epilepsy.10
Although public attitudes toward epilepsy have improved
significantly over the last 40 years,9 recent surveys indicate
that, at least in some, this improvement may have slipped
back.11
Need for awareness and knowledge to change
perceptions
Raising public awareness and knowledge is essential to
fight stigma effectively.12 Awareness should encompass the
notion that some forms of epilepsy can be life-threatening,
due to the risk of seizure-related injuries, status epilepticus
and, in particular, sudden unexpected death in epilepsy
(SUDEP). As stated in the 2012 US Institute of Medicine’s
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report, “targeted educational programs and counseling for
people with epilepsy and their families are clearly indicated,
but this is not enough. Initiatives are also required that focus
on changing negative public attitudes.”12,13
Through awareness activities conducted by IBE associa-
tions in many countries, public knowledge about epilepsy in
Europe has improved compared to 30–40 years ago.9
Although this has been achieved on tiny budgets in individ-
ual countries, trans-European awareness campaigns could
have a much greater impact and should be funded in line
with the global commitment of the European Commission
to fight stigma.
Obtaining accurate information on stigma, on the preva-
lence and cost of epilepsy, and on epilepsy mortality, should
also be considered a priority. Finally, the magnitude of the
social and economic problems raised by stigma affecting
persons with epilepsy requires a long-term, systemic and
rigorously evaluated approach whereby EU-funded actions
and their outcomes should be closely monitored and
reported.
Legislation
In many countries, laws affecting the lives of people with
epilepsy fail to adequately protect their human rights and, in
some cases, even violate those rights. In yet other countries,
there is a complete absence of legislation in this area. IBE
and ILAE, within the framework of the ILAE/IBE/World
Health Organization (WHO) Global Campaign Against Epi-
lepsy, performed a comparative analysis of epilepsy-related
legislation in >50 countries worldwide, which revealed that
many laws affecting people with epilepsy fail to meet
today’s international human rights standards (http://www.
globalcampaignagainstepilepsy.org/epilepsy-and-legislation/).
Well-crafted legislation thus needs to be developed to address
these deficiencies and to improve equity in access to health-
care services and community integration for people with epi-
lepsy. One specific example is the right to drive, which is an
important component of a person’s quality of life, and shown
to have large inconsistencies across European countries in the
past.14 The recent EC Directive on Driving aims at promoting
harmonization on this issue.15
Ensuring Adequate Standards of
Care
Epilepsy is characterized by a large variety of syndromes
and etiologies with different clinical manifestations and
prognoses. Because of this, adequate care of people with
epilepsy is dependent on the availability of diagnostic ser-
vices with a high degree of expertise and, in many cases,
ability to optimize complex and specialized treatments.
Standards of care should be based on a network of physi-
cians and/or services providing stepwise access to different
levels of specialized expertise offering a balanced relation-
ship between costs and patient’s benefits.16
The NICE (National Institute for Health and Care Excel-
lence) guidelines recommend that all adult and children
having a first seizure should be seen as soon as possible by a
specialist in the management of the epilepsies to ensure pre-
cise and early diagnosis and initiation of therapy as appro-
priate to their needs (http://www.nice.org.uk/guidance/
cg137/chapter/guidance#following-a-first-seizure). If ini-
tial treatment fails to control seizures, patients should be
evaluated ideally at a comprehensive epilepsy center in
order to reassess the diagnosis and identify the most appro-
priate therapeutic options.
The point prevalence of epilepsy is approximately 0.7%
of the population, and up to one third of individuals with
epilepsy fail to achieve sustained seizure freedom with
available medications. Based on these figures, and consider-
ing that most European comprehensive epilepsy centers
manage between 2,000 and 4,000 patients, at least one such
center per a population of 1–2 million people should be
accessible. These centers, in turn, should have access to
high-resolution magnetic resonance imaging (MRI) and in-
patient video–electroencephalography (EEG) long-term
recording (epilepsy monitoring unit), and a multidisci-
plinary team that should also include neuropsychologists,
Table 1. Epilepsy facts in Europe
There are 6 million people with epilepsy in Europe2
Epilepsy is a disease with many different syndromes and hundreds of different causes
There are ~400,000 new cases in Europe each year, that is, one new case every minute
100,000 children and adolescents are diagnosed with epilepsy each year2
130,000 people ≥65 years of age diagnosed each year2
About 50% of patients with epilepsy feel stigmatized3
The death rate in people with epilepsy is 2–3 times higher than in the general population4,5
Life expectancy is reduced by 2–10 years4,5
Patients with epilepsy have fourfold risk of comorbidities, which reduce the quality of life6
One third of patients with epilepsy are not controlled by current treatments7
There are no therapies to prevent or cure epilepsy
There are no biomarkers to identify patients at risk for epilepsy
The total cost of epilepsy in Europe is €20 billion per year8
The total European population is 729 million (<15 years: 137 million; ≥65 years 129 million; Source: Eurostat.Eu). Numbers are rounded.
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and/or psychiatrists. Genetic counselling should also be
available. The possibility of recording from implanted elec-
trodes (invasive EEG) and offering epilepsy surgery should
be available in comprehensive epilepsy centers that can
assemble sufficient expertise and a sufficient annual number
of surgical procedures to ensure optimal performance.
Although robust evidence is lacking to ascertain this num-
ber, the EU-funded E-PILEPSY pilot network of coopera-
tion on epilepsy surgery has recently proposed to set this
number to 15 resective surgeries per year. Patients should
be given the opportunity to participate in high-quality clini-
cal research where appropriate.
There seems to be considerable variability in quality of
epilepsy care across countries within Europe, especially for
epilepsy surgery,17–20 emphasizing the need for harmoniza-
tion program and European guidelines outlining minimum
standards of care.
Identifying Priorities for
Epilepsy Research
Epilepsy in the developing brain
Epilepsies are the primary cause of neurologic morbidity
in children, with 40% of incident cases of epilepsy occurring
before the age of 15.21 However, the etiology of 55–75% of
epilepsies remains unknown.22 Seizures in preterm and
newborn babies remain the most frequent neurologic prob-
lem in neonatology intensive care units, but it is still unclear
whether early seizures are the cause of long-term neurologic
deficits. Studies on animal models indicate that epileptogen-
esis and cognitive deficits result from early seizures, but the
underlying mechanisms are incompletely understood.23 The
main molecular targets of current antiepileptic drugs
(AEDs) also regulate developmental processes, such as cell
proliferation, migration, differentiation, and physiologic
apoptotic cell death.24,25 Therefore, cognitive deficits found
in about 25% of children with epilepsy could also be related
to adverse effects of AEDs.26 Overall, childhood epilepsies
have specificities that cannot be addressed by considering
them as a subset of adult epilepsies. Convergence of con-
cepts, data, networks, and technologic and regulatory
improvements have emerged in the field of pediatric epilep-
tology during the last decade, setting the stage to address the
short-, medium-, and long-term fundamental questions
delineated below.
Short- and medium-term research priorities should focus
on understanding mechanisms of childhood epilepsies, and
more specifically include: (1) postgenomic research on
developmental brain disorders with parallel studies on sur-
gical tissue to allow investigations from bench to bedside
and back; (2) studies on the causal heterogeneity and phe-
notypic diversity or similarity of pediatric epilepsies; (3)
development of experimental models to elucidate mecha-
nisms of epileptogenesis in the immature brain; (4) inves-
tigations of the mechanisms underlying cognitive
dysfunction in age-related epileptic encephalopathies and
the interference between epileptogenic networks and nor-
mal brain function; and (5) innovative trial designs to
investigate therapeutic interventions in small but homoge-
neous populations of patients with age-related epileptic
encephalopathies. Long-term research priorities should
translate mechanistic knowledge into treatments, with the
aim to (1) develop innovative strategies to prevent and
cure childhood epilepsies and to prevent cognitive deterio-
ration; and (2) identify age- and syndrome-specific drug
targets that can be translated into drug discovery and novel
trial designs.
Novel targets for innovative diagnostics and treatment
of epilepsy
Second-generation AEDs have improved medical man-
agement by providing more treatment options—sometimes
with better tolerability and safety and fewer interactions
with concomitant medications than first-generation AEDs
—but have failed to demonstrate superior efficacy over
these older AEDs, such as valproic acid and carba-
mazepine.27 This likely reflects the fact that all current
AEDs target neurotransmitter release or receptors and ion
channels involved in regulating neuronal excitability, but
not the mechanisms inherent to the pathophysiology of drug
resistance and/or the disease. For a major breakthrough in
epilepsy therapy, we need to identify novel drug targets that
could lead to the discovery of new medications that are
effective against currently drug-resistant epilepsy, or able to
alter the course of the disease.28 Recent progress in under-
standing the mechanisms involved in epileptogenesis, sei-
zure emergence (ictogenesis), and drug resistance holds
promise for the discovery of new targets not only for better
treatments, but also for innovative biomarker-based diag-
nostic tools.29–31
Nonneuronal modulation of epileptic activities: glial cells
and inflammatory processes
Glial cells (astrocytes and microglia) undergo phenotypic
and functional alterations in epilepsy. The emerging con-
cept of gliotransmission and the role of astrocytes as signal-
ing units in the so-called tripartite synapse, support the
crucial contribution of glial cells to changes in neuronal
function.32 New evidence from experimental models of epi-
lepsy and different drug-resistant forms of human epilepsy
shows that glial cells release neuromodulatory molecules
(e.g., glutamate, ATP, cytokines), which can play an impor-
tant role in seizure generation, maladaptive plasticity, and
comorbidities.33 Although glial cells offer potential targets
for innovative diagnostics and treatments for epilepsy, open
questions about their role in seizure generation still need to
be addressed, and in particular: (1) the role of glia in seizure
initiation versus spread versus termination; (2) functional/
phenotypic changes in glia during ictogenesis and epilepto-
genesis by differentiating homeostatic from deleterious
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effects; (3) the role of glia in pharmacoresistance and
blood–brain barrier dysfunction; (4) the role of glia in
comorbidities; and (5) strategies to be used for therapeutic
interventions targeting glial function.
In addition, increasing evidence has accumulated that
inflammatory mechanisms can play an important role both
in epileptogenesis and seizure generation.34 These mecha-
nisms thus represent an attractive target for novel
antiseizure and antiepileptogenic medications. As for
glia-targeting interventions, however, identifying effective
antiinflammatory treatments for epilepsy requires address-
ing a number of challenges, including (1) finding master
regulators of the pathologic inflammatory cascade in
epilepsy; (2) characterizing the time- and cell-specific
expression of inflammation-linked targets during epilepto-
genesis, as well as their commonalities and differences in
different models; (3) understanding whether combined anti-
inflammatory treatments may lead to improved clinical out-
comes compared to individual interventions; (4) identifying
the optimal target population and modalities of intervention;
and (5) searching for biomarkers of glia activation, brain
inflammation, and altered blood–brain barrier function, to
improve diagnosis, patients stratification, and prognosis.
Noncoding genes as therapeutic targets
About 85% of the human genome is actively transcribed
as noncoding RNA, which represents a major layer of regu-
latory control of gene expression and a potential target for
epilepsy treatments.35 In particular, microRNAs are a class
of small noncoding RNAs with critical roles in brain devel-
opment and function that could be used for therapeutic or
diagnostic purposes. Indeed, the levels of several micro-
RNAs are altered both in brain and blood by seizure activ-
ity in animal models as well as in resected human epileptic
tissue.35 Priority research objectives in this area include the
following: (1) improving our understanding of noncoding
RNA in regulating gene expression in epilepsy; (2) devel-
oping methods for targeting noncoding RNAs for therapeu-
tic benefit; (3) determining the role of variants in
noncoding RNA sequences in the human genome as risk
factors for epilepsy; and (4) identifying microRNAs in
body fluids which could serve as molecular biomarkers of
epileptogenesis.
Gene therapy and cell therapy
Gene therapy and cell therapy have gained attention as
potential innovative therapeutic strategies for epilepsy.36,37
A specific potassium channel Kv1.1 and combinatorial
approach of neuropeptide Y and its receptor Y2 are recent
examples demonstrating the efficacy of one-time gene ther-
apy in various chronic models of epilepsy.36,38 A combina-
torial gene therapy approach with FGF-2 and brain-derived
neurotrophic factor (BDNF), administered shortly after the
epileptogenic insult, demonstrated that gene therapy can
also exert antiepileptogenic effects.39 Optogenetic, coupled
with gene therapy–mediated halorhodopsin (NpHR) based
inhibition of excitatory neurons or ChR2 (channelrhodop-
sin-2) based activation of interneurons, has been shown to
suppress seizure activity in various in vitro and in vivo mod-
els of epilepsy.40 Animal studies also suggest that stem cells
derived from the patient’s own somatic cells (skin fibrob-
lasts) or so-called induced pluripotent stem (iPS) cells, can
differentiate into c-aminobutyric acid (GABA)ergic neu-
rons, and could be transplanted to inhibit seizures.41
The main open research questions in this field relate to
the optimization of the safety and efficacy of these therapies
to a level appropriate for undertaking clinical trials. Direc-
tions to investigate should include (1) manipulation of RNA
interference or epigenetic mechanisms, (2) overexpression
of native proteins, and (3) development of closed-loop opto-
genetics.
Improving epilepsy surgery outcomes
Epilepsy surgery is currently the most effective treatment
for patients with drug-resistant epilepsy, yet still failing in a
substantial proportion of patients.42 Thus, we need to con-
tinue improving the performance of presurgical investiga-
tions and surgical therapies. Specific objectives to be
pursued by further research include the following: (1) devel-
opment of tools to better determine noninvasively the extent
of the epileptogenic zone; (2) characterization of dysfunc-
tional large brain networks, which may allow selection of
candidates for other therapies such as neuromodulation; (3)
development of more powerful scalp and intracranial elec-
trodes to be used in humans; (4) development of novel surgi-
cal approaches including magnetic resonance imaging
(MRI)–guided laser ablation of the epileptogenic zone and
closed-loop stimulation of the nervous system.43–45
What is required for prevention and cure?
Currently available AEDs have not been found to prevent
epileptogenesis, or to alter the natural course of the disease,
and their effect is essentially symptomatic.30 Preclinical
proof-of-concept studies have revealed that about a dozen
different treatments can reduce the development of epilepsy
and/or its severity or development of comorbidities after
brain insults such as status epilepticus or traumatic brain
injury (TBI).30 However, many of these treatments are unli-
kely to proceed to clinic, for a variety of reasons such as
high risk of adverse effects, unfeasible routes of administra-
tion, or lack of adequately powered preclinical studies.
Moreover, little attention has been paid to age-specificity of
mechanisms of epileptogenesis, or the presumed relevance
of the animal model to the clinical situation. To address
these limitations, future efforts should be targeted to do the
following: (1) identify epileptogenic mechanisms for differ-
ent epilepsy syndromes at different ages, including genes
and genetic variability (application of state-of-the art bioin-
formatics could be used to analyze available [“omics”] data,
and predict disease pathways and therapeutic targets); (2)
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design tools for higher-throughput screening of novel treat-
ments, including innovative drug screening assays, such as
the genetic zebra fish models of epilepsies; (3) develop tech-
nologies for higher throughput, easier to use video–elec-
troencephalography (EEG) monitoring and drug delivery in
animal models; (4) develop age- and syndrome-relevant
models for studying mechanisms of epileptogenesis and
efficacy of treatments; and (5) Provide resources for valida-
tion of novel targets for both acquired and genetic epilepsies
in clinically relevant animal models with clinically applica-
ble endpoints.
Although preclinical efforts are likely to yield attractive
antiepileptogenic candidate treatments, several obstacles
need to be overcome for clinical translation. The main
challenges include: (1) the identification of the right target
population to be tested, (2) the availability of relevant
biomarkers for patient stratification and prediction of treat-
ment response, (3) the difficulty in recruiting patients into
clinical trials where only a minority would be expected to
develop epilepsy, and (4) the reluctance of the pharmaceuti-
cal industry to invest into an area where therapeutic benefits
may take several years to be demonstrated. For instance, the
risk of epilepsy after TBI, stroke, or cerebral infection
varies between 3% and 50% depending on various risk
factors.46–48 High-risk patients may be suitable candidates
for clinical trials for antiepileptogenesis, provided that new
biomarkers will allow identifying the endophenotypes
associated with a higher risk of epilepsy.49
Proposal for a European roadmap for translational
research
Based on the above considerations, a European roadmap
is proposed aimed at supporting target-driven discovery and
development of antiepileptogenic drugs for prevention and
cure of epilepsy. The roadmap should involve the following:
(1) establishing a preclinical European Consortium for
Antiepileptogenesis studies, and a clinical European Consor-
tium for Antiepileptogenesis studies; (2) establishing a
European Biomarker Consortium for identification of differ-
ent endophenotypes of patients at high risk for epilepsy and
disease progression (a subproject could include the estab-
lishment of a European Epilepsy database); (3) creating an
academia-industry partnership to develop innovative tech-
nologies for preclinical and clinical seizure detection and
drug-delivery; (4) implementing comparative preclinical
and clinical proof of concept studies of antiepileptogenic
drugs for prevention of epilepsy; and (5) exploring the feasi-
bility of developing a European Epilepsy Surveillance Sys-
tem to monitor the epidemiology over time and thus effects
of future preventive interventions.
Comorbidities of epilepsy with focus on aging and
mental health
Cognitive, behavioral, and psychiatric comorbidities in
epilepsy are frequent and can affect profoundly quality of
life, sometimes more than the seizures per se.50–52 They
often go underdiagnosed due to an overriding focus by
physicians on suppressing the seizures, and may in fact be
precipitated by the treatment used to control the seizures.
In children and early onset epilepsies, developmental
hindrance is very common, with major behavioral problems
in children being autism as well as hyperactivity and atten-
tion deficit disorders.53 The increased incidence of autism
spectrum disorders in epilepsy, compared to other chronic
disorders such as asthma, diabetes, and migraine, has been
interpreted as probably reflecting an epilepsy-specific
comorbidity.54 Further research on the origin of comorbidi-
ties and their management can impact positively on the
patients’ quality of life, and improve the cost-effectiveness
of care to this population.
Switching focus from chronic to new-onset epilepsies
Investigations in patients with chronic epilepsy suggest
that many cognitive problems may develop in the early
phases of epilepsy, and that a large portion of the impair-
ments seen in chronic epilepsy results from developmental
hindrance. In fact, recent studies in large groups of untreated
new-onset epilepsies demonstrate that, dependent on the
type of epilepsy, cognitive impairments are present in nearly
half of the patients at the time of first diagnosis.55 Similarly,
children with new-onset epilepsies are often impaired from
the beginning of the disease,56 and there is evidence that
academic and behavioral problems in children antedate the
first recognized seizure.57 Like cognitive impairment,
psychiatric comorbidity is now considered not only a possi-
ble consequence but also a precursor of epilepsy, possibly as
an expression of a common underlying brain pathology.58–60
Overall, existing evidence indicates that early and success-
ful interventions may protect against negative cognitive
development. Successful seizure control with AEDs can
help to preserve cognitive capabilities and mental health,
but it may also cause additional problems.61 Another open
question is whether the comorbidities of epilepsy may
accelerate mental aging and promote cognitive decline. An
early epidemiologic study demonstrated a greater frequency
of neurodegenerative conditions like Alzheimer’s or Parkin-
son’s disease in epilepsy patients compared to individuals
without epilepsy.62
Setting the research priorities
Priorities for future research in this area should include
(1) identification of factors that lead to cognitive impair-
ment or behavioral and psychiatric disturbances; (2) investi-
gation of the relationship between disease development and
cognitive and behavioral comorbidity, elucidating the role
of the latter as a precursor as well as a consequence of
seizure occurrence; (3) assessment of large cohorts of
patients using multimodal and, whenever possible, longitu-
dinal studies, coupled with detailed clinical phenotyping
and appropriate omics; (4) search for metabolic, functional,
Epilepsia, 56(11):1687–1695, 2015
doi: 10.1111/epi.13201
1692
M. Baulac et al.
or molecular biomarkers that could allow early identifica-
tion of patients at risk for the development of severe cogni-
tive impairment; and (5) elucidation of the mechanisms
responsible for AED-related cognitive impairment.
Conclusions
The purpose of ERF2013 was to propose a roadmap high-
lighting how the Written Declaration on Epilepsy, approved
by the European Parliament in 2011, can be implemented in
practice, and what resources are needed. A clear message
was delivered to politicians and to policy makers that further
funding for epilepsy research is needed within the next EU
framework program (Horizon 2020). Major research prior-
ity areas discussed at the Forum (Table 2) include (1) under-
standing epilepsy in the developing brain; (2) identifying
new targets for innovative diagnostics and treatments; (3)
prevention and cure of epilepsy; and (4) understanding epi-
lepsy comorbidities with special focus on aging and mental
health. In addition, there was consensus that increasing
awareness of epilepsy at every level of society is necessary
to reduce social burden and the stigma associated with epi-
lepsy. The need was stressed for a European-wide epilepsy
awareness campaign, supported by the European Commis-
sion, in conjunction with targeted initiatives at national and
regional levels. The annual European Epilepsy Day, hosted
on the second Monday in February for the last 4 years in the
European Parliament, has been a major success, and its con-
tinuation was encouraged. Finally, the crucial importance of
access to optimal standards of epilepsy care was empha-
sized, including the need for specialized epilepsy centers,
each serving a population of 2–3 million inhabitants
(4,000–6,000 patients). Support from politicians and deci-
sion makers in Member States and at EU level is essential to
improve quality of epilepsy care.
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Sankar (U.S.A.), Dieter Schmidt (Germany), Margitta Seeck (Swizerland),
Kevin J Staley (U.S.A.), Maria Thom (United Kingdom), Torbj€orn Tomson
(Sweden), Patrick Van Bogaert (Belgium), and Annamaria Vezzani (Italy).
Table 2. Roadmap to reduce burden and stigma, improve access to care, and outline the research priorities of epilepsy
in Europe
Reduce stigma and burden of epilepsy
Need for public awareness and improved public knowledge to change perceptions
Monitor the impact of funded actions
Address legislation discriminating against people with epilepsy
Improve standards of epilepsy care
Ensure access to specialist care after a first seizure
Ensure access to epilepsy specialists for difficult-to-treat patients
Ensure access to epilepsy centers with multidisciplinary specialized expertise
Harmonize infrastructure and guidelines for epilepsy care across Europe
Understanding and managing epilepsy in the developing brain
Understand the mechanisms underlying childhood epilepsies
Translate mechanistic understanding into effective therapies
New targets for innovative diagnostics and treatment
Assess the therapeutic potential of nonneuronal modulation of epileptic activities, that is, glial cell function and inflammatory processes
Assess the potential of noncoding genes as targets for future therapies
Improve tools to accurately delimitate the epileptic focus with a surgical perspective
Investigate multidisciplinary treatments, including gene therapy, cell therapy, optogenetics
Prevention and cure of epilepsy
Understand the mechanisms of epileptogenesis in different settings to design innovative disease-modifying treatments
Apply novel tools in treatment discovery and screening
Remove obstacles in translating preclinical discoveries to the clinic
Establish European-wide preclinical and clinical consortia for antiepileptogenesis and biomarker identification studies
Comorbidities of epilepsy with focus on aging and mental health
Identify factors leading to cognitive impairment or behavioral and psychiatric comorbidities in patients with epilepsy
Perform studies in large cohorts using detailed phenotyping to assess the relationship between disease development and cognitive and behavioral
comorbidity
Search for biomarkers that could allow early identification of patients at risk for developing severe cognitive impairment
Understand mechanisms underlying AED-related cognitive impairment
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